Beaird Harris Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Beaird Harris Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-600	Closed	-$1.78K	–	512
2024 Q2	$1.78K	Hold	600	–	–	﹤0.01%	546
2024 Q1	$2.72K	Hold	600	–	–	﹤0.01%	440
2023 Q4	$3.43K	Hold	600	–	–	﹤0.01%	417
2023 Q3	$2.76K	Hold	600	–	–	﹤0.01%	342
2023 Q2	$3.88K	Hold	600	–	–	﹤0.01%	338
2023 Q1	$4.52K	Hold	600	–	–	﹤0.01%	326
2022 Q4	$6.08K	Hold	600	–	–	﹤0.01%	386
2022 Q3	$6K	Buy	+600	New	+$6.58K	﹤0.01%	322
2022 Q2	–	Sell	-600	Closed	-$6K	–	399
2022 Q1	$6K	Buy	600 +300	+100%	+$2.84K	﹤0.01%	400
2021 Q4	$4K	Buy	+300	New	+$4.55K	﹤0.01%	485

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Beaird Harris Wealth Management's ABCL Position: Q3 2024 in Review

Beaird Harris Wealth Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 600 shares — an estimated $1.78K sold.

Beaird Harris Wealth Management first reported a position in ABCL in Q4 2021 and held it in 10 quarters. The position peaked at $6.08K in Q4 2022. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Beaird Harris Wealth Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Beaird Harris Wealth Management sold 600 AbCellera Biologics shares in Q3 2024, an estimated $1.78K.
Beaird Harris Wealth Management first reported a position in AbCellera Biologics in Q4 2021 and held it in 10 quarters.
Beaird Harris Wealth Management's AbCellera Biologics position peaked at $6.08K in Q4 2022.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Beaird Harris Wealth Management's 13F filing for Q3 2024, filed 2 Dec 2024.